PDCD1 and ovarian carcinoma: The IPS values (IPS-CTLA-4_pos and IPS-PD-1/PD-L1/PD-L2_pos) as the alternative of the ovarian cancer patients’ responses to anti-CTLA-4 and anti-PD-1/PD-L1 treatment were increased in the high TMEscore group (Figure 5D, 5E).